Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, China.
PLoS One. 2011;6(11):e28111. doi: 10.1371/journal.pone.0028111. Epub 2011 Nov 30.
The worldwide spread of H1N1 avian influenza and the increasing reports about its resistance to the current drugs have made a high priority for developing new anti-influenza drugs. Owing to its unique function in assisting viruses to bind the cellular surface, a key step for them to subsequently penetrate into the infected cell, hemagglutinin (HA) has become one of the main targets for drug design against influenza virus. To develop potent HA inhibitors, the ZINC fragment database was searched for finding the optimal compound with the core hopping technique. As a result, the Neo6 compound was obtained. It has been shown through the subsequent molecular docking studies and molecular dynamic simulations that Neo6 not only assumes more favorable conformation at the binding pocket of HA but also has stronger binding interaction with its receptor. Accordingly, Neo6 may become a promising candidate for developing new and more powerful drugs for treating influenza. Or at the very least, the findings reported here may provide useful insights to stimulate new strategy in this area.
甲型 H1N1 禽流感在全球范围内的传播以及越来越多的关于其对现有药物的耐药性的报告,使得开发新的抗流感药物成为当务之急。由于血凝素 (HA) 在协助病毒与细胞表面结合方面具有独特的功能,这是病毒随后进入感染细胞的关键步骤,因此它已成为针对流感病毒的药物设计的主要目标之一。为了开发有效的 HA 抑制剂,使用核心跳跃技术从 ZINC 片段数据库中搜索寻找最佳化合物。结果得到了 Neo6 化合物。随后的分子对接研究和分子动力学模拟表明,Neo6 不仅在 HA 的结合口袋中呈现出更有利的构象,而且与受体的结合相互作用也更强。因此,Neo6 可能成为开发治疗流感的新型强效药物的有希望的候选物。或者至少,这里报告的研究结果可能会提供有用的见解,以激发该领域的新策略。